Nymox Pharmaceutical Corporation

Equities

NYMXF

BSP733981026

Biotechnology & Medical Research

Market Closed - OTC Markets 12:26:43 2024-03-28 pm EDT 5-day change 1st Jan Change
0.4 USD -4.76% Intraday chart for Nymox Pharmaceutical Corporation 0.00% -32.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH CI
Nymox Pharmaceutical Corporation announced that it has received $2 million in funding CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding CI
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results CI
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors CI
Fed Outlook Weighs on Exchange-Traded Funds, Equity Futures Premarket Thursday MT
Nymox Pharmaceutical Receives Delisting Notice From Nasdaq MT
Nymox Pharmaceutical Corporation(OTCPK:NYMX.F) dropped from NASDAQ Composite Index CI
Nymox Pharmaceutical Corporation Announces Removal of Board of Directors CI
Nymox Pharmaceutical Corporation Announces Termination of Christopher R. Riley as Chief Financial Officer CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Index CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Growth Index CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Index CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Growth Index CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nymox Pharmaceutical Corporation Auditor Raises 'Going Concern' Doubt CI
Nymox Pharmaceutical Names Christopher Riley as CFO MT
Nymox Pharmaceutical Corporation Announces Appointment of Christopher R. Riley as Chief Financial Officer CI
Nymox Pharmaceutical Gets Nasdaq Extension to Comply With Listing Requirements; Shares Rise MT
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chart Nymox Pharmaceutical Corporation
More charts
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Nymox Pharmaceutical Corporation - OTC Markets
  4. News Nymox Pharmaceutical Corporation
  5. Nymox Pharmaceutical : Expects to Provide Guidance on Fexapotide Regulatory Filing This Quarter; Shares Drop